Effectiveness of Janus Kinase Inhibitors for the Management of Atopic Dermatitis and Concomitant Occupational Allergic Contact Dermatitis: A Real-Life Study
Restricted accessLetterFirst published online November, 2025
Effectiveness of Janus Kinase Inhibitors for the Management of Atopic Dermatitis and Concomitant Occupational Allergic Contact Dermatitis: A Real-Life Study
NapolitanoM, FabbrociniG, PatrunoC. Allergic contact dermatitis in patients with atopic dermatitis: A retrospecitive study. J Allergy Clin Immunol Pract. 2019; 7(7):2459–2461.
2.
CaiazzoG, CaiazzoA, NapolitanoM, et al.The use of JAK/STAT inhibitors in chronic inflammatory disorders. J Clin Med. 2023; 12(8):2865.
3.
JohnsonH, GuentherJ, AdlerBL, et al.Janus kinase inhibitors: A promising therapeutic option for allergic contact dermatitis. Cutis., 2023; 111(2):92–105.
4.
BaltazarD, ShinamotoSR, HamannCP, et al.Occupational airborne allergic contact dermatitis to invasive Compositae species treated with abrocitinib: A case report. Contact Dermatitis. 2022; 87(6):542–544.
5.
MuddebihalA, SardanaK, SinhaS, et al.Tofacitinib in refractory Parthenium-induced airborne allergic contact dermatitis. Contact Dermatitis. 2023; 88(2):150–152.
6.
Ch’enPY, Al-SaedyM, SongEJ. Upadacitinib as a treatment for co-existent allergic contact dermatitis and psoriasis. JAAD Case Rep. 2024; 44:20–22.
